University of British Columbia
Effects of nasal budesonide on nasal inflammation and epigenetic age in patients with allergic rhinitis under conditions of repeated acute exposure to allergen or diesel exhaust
Abstract
dc:descriptionIntroduction: Allergic rhinitis (AR), reflecting nasal inflammation from aeroallergens, is typically treatable with nasal corticosteroids (NCS). However, the relative effects of allergen and diesel exhaust (DE) on nasal endpoints, the efficacy of NCS therapy following exposure to DE, as well as the effects of NCS therapy on exposure-related nasal epigenetic age acceleration (EAA) are all unknown. Objective: To narrow these knowledge gaps by investigating the effects of budesonide on AR-related nasal inflammation and nasal EAA, following allergen and DE exposure. Methods: In a double-blinded randomized crossover trial, twenty healthy non-smokers with AR used once-daily budesonide and placebo nasal spray for ≥4 weeks each, with an intervening ≥4-week washout. Initial and re-exposure to allergen and DE was completed over consecutive days in separate periods preceded by ≥2 weeks of pre-treatment/washout. Nasal lavage fluid, nasal brushings, peak nasal inspiratory flow (PNIF), and total nasal symptom scores (TNSS) were collected at treatment baseline, and before and 24h after each exposure. PNIF and TNSS were additionally collected 0.5h post-exposure. Nasal cytokines and EAA were quantified using multiplex assays and Illumina EPIC arrays, respectively. Results: Reductions in nasal IL-5 following budesonide pre-treatment persisted 24h after initial and re-exposure to allergen and DE, despite their pro-inflammatory effects. Budesonide-mediated reductions in IL-17A persisted 24h after initial DE exposure. Budesonide increased PNIF 24h after initial and re-exposure to allergen, and at 0.5h after initial exposure and 24h after re-exposure to DE. Allergen-induced TNSS were suppressed by budesonide 0.5h and 24h after re-exposure. Budesonide decreased proportions of total leukocytes and granulocytes despite the pro-inflammatory effects of allergen and DE exposure. Budesonide and allergen/DE exposures modulated nasal EAA variably across different epigenetic clocks. Discussion: These results provide evidence for prophylactic nasal budesonide spray attenuating nasal inflammation and modulating nasal EAA in patients with AR, before and after repeated acute exposures to allergen and DE. NCS agents may serve as effective therapeutic interventions to mitigate the global burden of morbidity and mortality caused by air pollution.
Degree
thesis:*- Name thesis:degree_name
- Master of Science - MSc
- Level thesis:degree_level
- master's
- Discipline thesis:degree_discipline
- Experimental Medicine
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Halbe, Eashan
- Contributors dc:contributor
-
- Carlsten, Christopher Russell
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/91239